MajesTEC-9 Results : Teclistamab Outperforms PVd & Kd in Relapsed Myeloma: | EHA 2026

In this video, we review the important results from the phase 3 MajesTEC-9 trial presented at EHA 2026. MajesTEC-9 compared teclistamab, a BCMA-directed bispecific antibody, with physician’s choice of PVd (pomalidomide, bortezomib, dexamethasone) or Kd (carfilzomib, dexamethasone) in patients with relapsed/refractory multiple myeloma who had previously received lenalidomide and an anti-CD38 antibody. If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/6286... For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer! Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_so... Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.